Taken together, these findings establish that the main target of SBT-100 is the SH2 domain and this is consistent with our published report that SBT-100 inhibits the STAT3 pathway of uveitogenic Th17 and Th1 cells that mediate uveitis [12]. Here, STAT3 is linked to uveitis.